Please login to the form below

Not currently logged in
Email:
Password:

P&G and Teva form consumer venture

Procter & Gamble and Teva Pharmaceutical have agreed to combine their portfolios of OTC medicines in all markets outside North America to create a consumer healthcare joint venture

The Procter & Gamble Company and Israel's Teva Pharmaceutical have agreed to combine their portfolios of over-the-counter (OTC) medicines in all markets outside North America to create a consumer healthcare joint venture that will launch with annual sales of more than $1bn.

In addition, the partnership will explore opportunities for prescription-to-OTC switches in global markets including in North America.

"This new business model combines P&G's strong brand-building, consumer-led innovation and go-to-market capabilities with Teva's broad geographic reach, its experience in R&D, regulatory and manufacturing and its extensive portfolio of products," according to the companies. Teva will have global responsibility for manufacturing to supply the joint venture markets and P&G's existing North American business.

The partnership will immediately expand the number of channels and geographic markets in which each company's OTC products are sold and will help P&G with the global expansion of OTC brands including Vicks, Metamucil and Pepto-Bismol, the partners said.

The deal, which is expected to close in the fall of 2011, will create a joint venture 51 per cent owned by P&G and 49 percent owned by Teva that could eventually have annual sales reaching $4bn, according to the companies.

Tom Finn, president of P&G's healthcare business, will serve as the joint venture's chairman, while P&G's Briain Debuitleir will serve as its chief executive officer. The venture's chief financial officer will be P&G's Markus Xander, and its chief operating officer will be Teva's Eli Shani.

25th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics